news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
The US Patent and Trademark Office has recently granted a new patent for Da Volterra in the USA. The patent received number 9,968,562 and includes claims covering composition of matter and methods of use for DAV132, our innovative product designed to protect the intestinal microbiota in patients taking antibiotics.
This patent reinforces our intellectual property portfolio and comes as a complement to the already 100+ patents protecting DAV132 worldwide.
